PP
JNCE

Paloma Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Paloma Partners’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17,500
Closed -$59K – 2027
2018
Q4 		$59K Buy
+17,500
New +$81.8K ﹤0.01% 1157
2018
Q2 		– Sell
-16,707
Closed -$373K – 2334
2018
Q1 		$373K Sell
16,707
-1,300
-7% -$28.9K 0.01% 1516
2017
Q4 		$230K Buy
+18,007
New +$265K ﹤0.01% 1666
2017
Q2 		– Sell
-9,612
Closed -$212K – 2506
2017
Q1 		$212K Buy
+9,612
New +$204K ﹤0.01% 1839

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Paloma Partners's JNCE Position: Q1 2019 in Review

Paloma Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2019, closing a stake of 17,500 shares — an estimated $59K sold.

Paloma Partners first reported a position in JNCE in Q1 2017 and held it in 4 quarters. The position peaked at $373K in Q1 2018. 80 funds tracked by Wall St. Rank hold JNCE as of Q1 2019.

  • Paloma Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Paloma Partners sold 17,500 Jounce Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $59K.
  • Paloma Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Paloma Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $373K in Q1 2018.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.